THE Therapeutic Goods Administration (TGA) is reportedly considering an application to require vitamin B6 products to be sold exclusively by pharmacists.
Since 2020, the regulatory body has received 119 reports of peripheral neuropathy as a result of B6 poisoning.
Several medical bodies, including The Royal College of Pathologists of Australasia, have issued warnings following an increase in patients presenting with peripheral neuropathy.
The TGA has required a warning label for listed medicines with more than 10mg of B6 since 2022.
However, the body told ABC's 7.30 that it is now assessing whether B6 products containing between 5mg and 200mg should be required to be stored behind the counter "to prevent physical access by the public" and to be sold only by pharmacists.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Jan 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Jan 25
